• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RVTY alert in real time by email

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening

    Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay.

    T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcomes through intervention to prevent the natural progression of the disease and complications such as diabetic ketoacidosis (DKA). Over 9 million people worldwide live with T1D with more than 500,000 new cases diagnosed each year—90% without a family history.

    The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity's GSP® instrument using capillary dried blood spot (DBS) and venous specimens. The GSP® instrument's high throughput capability enables population-level screening for early-stage T1D in clinical practice, an important advance in the evolution of the standard of care. Regulatory submissions are planned for the U.S. FDA, IVDR and other major jurisdictions.

    "The expansion of autoantibody testing from research-use towards convenient, affordable, high-quality and high-throughput commercial platforms such as Revvity GSP may accelerate the transition to a new clinical standard of care where people with T1D are diagnosed as early as possible," said Shirley Gil Parrado, global head of autoimmune type 1 diabetes at Sanofi.

    In parallel, Revvity and Sanofi are also collaborating to expand access to Revvity's existing RUO product. Currently offered as an LDT at the CLIA and CAP accredited Revvity Omics laboratory in Pittsburgh, PA, Revvity will work to validate the assay in additional locations across its global laboratory network to facilitate worldwide access to the assay for clinical use.

    "Revvity Omics has built a reputation as a global leader in genomic testing for both rare and common conditions—pushing the boundaries of technology across multiple platforms. Today's announcement is a pivotal step forward, showing that we're not just capable but eager to further expand into non-rare diseases," said Dr. Madhuri Hegde, senior vice president and chief scientific officer at Revvity. "This collaboration reinforces the value of collaboration across biotech, improving patient outcomes by ensuring assays are available to identify the people who would benefit from therapeutics developed by the pharmaceutical industry."

    Factors Affecting Future Performance

    This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes", "intends", "anticipates", "plans", "expects", "estimates", "projects", "forecasts", "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    About Revvity

    At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

    With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

    Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251002034718/en/

    Investor Relations:

    Steve Willoughby

    [email protected]

    Media Relations:

    Chet Murray

    (781) 462-5126

    [email protected]

    Get the next $RVTY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY
    $SNY

    CompanyDatePrice TargetRatingAnalyst
    Sanofi
    $SNY
    9/8/2025$58.00Equal-Weight → Overweight
    Morgan Stanley
    Sanofi
    $SNY
    9/2/2025Hold → Buy
    Deutsche Bank
    Sanofi
    $SNY
    8/8/2025Neutral → Overweight
    Analyst
    Revvity Inc.
    $RVTY
    5/1/2025$115.00Neutral → Buy
    UBS
    Sanofi
    $SNY
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    Sanofi
    $SNY
    3/21/2025$65.00Neutral
    Goldman
    Sanofi
    $SNY
    1/30/2025Sell → Hold
    Deutsche Bank
    Revvity Inc.
    $RVTY
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    More analyst ratings

    $RVTY
    $SNY
    SEC Filings

    View All

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    9/26/25 9:41:22 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    9/22/25 2:59:02 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    9/17/25 12:03:12 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RVTY
    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

    New software further strengthens Revvity's market-leading position in in vivo imaging while empowering scientists with faster, more reproducible insights Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities—reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery. "Our Living Image Synergy AI software marks a significant leap forward in p

    9/29/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US

    MORRISTOWN, N.J., Sept. 26, 2025 /PRNewswire/ -- Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all patients in the US with a valid prescription. The program, first created for people without health insurance, will be available to all Americans regardless of insurance status, including those with commercial insurance or Medicare, to ensure affordable access to these critical medicines. Sanofi's expanded Insulins Valyou Savings Program now ensures no American needs to pay more than $35 per month for their Sanofi insulins. "Our announcement builds on an idea first championed by President Trump to

    9/26/25 8:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RVTY
    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RVTY
    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sanofi upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Sanofi from Equal-Weight to Overweight and set a new price target of $58.00

    9/8/25 8:38:18 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi upgraded by Deutsche Bank

    Deutsche Bank upgraded Sanofi from Hold to Buy

    9/2/25 8:23:14 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi upgraded by Analyst

    Analyst upgraded Sanofi from Neutral to Overweight

    8/8/25 7:58:21 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RVTY
    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Gonzales Anita covered exercise/tax liability with 149 shares, decreasing direct ownership by 3% to 4,340 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    9/17/25 4:05:09 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Krakowiak Maxwell covered exercise/tax liability with 559 shares, decreasing direct ownership by 4% to 12,217 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    9/17/25 4:05:14 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Michas Alexis P sold $44,505 worth of shares (500 units at $89.01) (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/28/25 4:05:04 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    $SNY
    Leadership Updates

    Live Leadership Updates

    View All

    Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

    TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

    6/9/25 10:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

    6/6/24 7:00:00 AM ET
    $AZN
    $IMAB
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi Bridging the Gap between the Homeless and Society via Futsal

    Sanofi hosted the founding ceremony of the homeless futsal club ‘Dream' and organized a friendly match as a part of the Helping Hands program Sanofi employees and ‘Dream' members interacted through the friendly match Sanofi has carried out social responsibility activities targeting the homeless and housing vulnerable groups since 2011 Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream' together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless. At the founding ceremony of the ‘Dream', held in Seongsu-dong, Seoul on the 17th, the club's first game

    10/17/23 9:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RVTY
    $SNY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

    Facility designed to advance the next generation of imaging systems Revvity, Inc. (NYSE:RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state's Research Triangle. The center consolidates Revvity's expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies. The new facility is staffed by R&D teams from across the organization, including software, hardware, and applied biology/applications teams, as well as those specialized in machine learning, optical, microCT, and ultrasound. Combined, these teams will hel

    9/2/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Financial Results for the Second Quarter of 2025

    Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a

    7/28/25 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials